SEPTIN4 and melanoma: Equivalent enhanced vaccine immunogenicity was obtained using peptides AH1-A5 (target in breast (24) and colon cancer (25) models in BALB/c mice) (Figure 3D), and ELA [from Melan-1/MART antigen and used in human melanoma vaccination experiments (26)], tested in HHD-DR1 mice (Figure 3E).